Back to Search
Start Over
Airway regulatory T cells are decreased in COPD with a rapid decline in lung function.
- Source :
-
Respiratory research [Respir Res] 2020 Dec 14; Vol. 21 (1), pp. 330. Date of Electronic Publication: 2020 Dec 14. - Publication Year :
- 2020
-
Abstract
- Background: Differences in the expression of regulatory T cells (Tregs) have been suggested to explain why some smokers develop COPD and some do not. Upregulation of Tregs in response to smoking would restrain airway inflammation and thus the development of COPD; while the absense of such upregulation would over time lead to chronic inflammation and COPD. We hypothesized that-among COPD patients-the same mechanism would affect rate of decline in lung function; specifically, that a decreased expression of Tregs would be associated with a more rapid decline in FEV <subscript>1</subscript> .<br />Methods: Bronchoscopy with BAL was performed in 52 subjects recruited from the longitudinal OLIN COPD study; 12 with COPD and a rapid decline in lung function (loss of FEV <subscript>1</subscript> ≥ 60 ml/year), 10 with COPD and a non-rapid decline in lung function (loss of FEV <subscript>1</subscript> ≤ 30 ml/year), 15 current and ex-smokers and 15 non-smokers with normal lung function. BAL lymphocyte subsets were determined using flow cytometry.<br />Results: The proportions of Tregs with regulatory function (FoxP3 <superscript>+</superscript> /CD4 <superscript>+</superscript> CD25 <superscript>bright</superscript> ) were significantly lower in COPD subjects with a rapid decline in lung function compared to those with a non-rapid decline (p = 0.019). This result was confirmed in a mixed model regression analysis in which adjustments for inhaled corticosteroid usage, smoking, sex and age were evaluated. No significant difference was found between COPD subjects and smokers or non-smokers with normal lung function.<br />Conclusions: COPD subjects with a rapid decline in lung function had lower proportions of T cells with regulatory function in BAL fluid, suggesting that an inability to suppress the inflammatory response following smoking might lead to a more rapid decline in FEV <subscript>1</subscript> . Trial registration Clinicaltrials.gov identifier NCT02729220.
- Subjects :
- Aged
Bronchoscopy
CD4 Lymphocyte Count
Case-Control Studies
Cross-Sectional Studies
Disease Progression
Female
Forced Expiratory Volume
Forkhead Transcription Factors analysis
Humans
Immunophenotyping
Interleukin-2 Receptor alpha Subunit analysis
Lung physiopathology
Male
Middle Aged
Phenotype
Pulmonary Disease, Chronic Obstructive diagnosis
Pulmonary Disease, Chronic Obstructive physiopathology
Smoking immunology
Smoking physiopathology
Lung immunology
Pulmonary Disease, Chronic Obstructive immunology
Smoking adverse effects
T-Lymphocytes, Regulatory immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1465-993X
- Volume :
- 21
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Respiratory research
- Publication Type :
- Academic Journal
- Accession number :
- 33317530
- Full Text :
- https://doi.org/10.1186/s12931-020-01593-9